Copyrighted Material
Total Page:16
File Type:pdf, Size:1020Kb
Index Note: Page numbers in italics refer to figures; page numbers in bold refer to tables Abelson 1 breakapart cluster fusion gene, 508 case study, 378, 391, 391–392 phenotypic studies, 283–284, 286, 287, 288, acitretin, 18 pathology, 381, 391, 392 289 acquired immunodeficiency syndrome (AIDS), alemtuzumab post-transplant, 281, 288–289, 288–289, 301, plasmablastic lymphoma, 427, 427 cutaneous T cell lymphoma, 18 302, 303, 303–304, 419 acral pseudolymphomatous angiokeratomas of Sézary syndrome, 18 primary, 281 children (APACHE), 67 T cell prolymphocytic leukemia, 453 pyogenic, 282 ACT-1 see CD25 antigen aleukemic leukemia cutis, 507 sarcomatoid see sarcomatoid anaplastic large actinic dermatitis, chronic, 52 ALK see anaplastic lymphoma kinase (ALK) cell lymphoma actinic prurigo, 52 ALK-1 breakapart probe, 13 secondary, 281 actinic reticuloid, 52, 356 allergic contact dermatitis, 37–39 small cell see small cell anaplastic large cell activation/proliferation markers clinical features, 37, 38 lymphoma anaplastic large cell lymphoma, 283 differential diagnosis, 39 type I cells, 281, 287, 288 definitions, 12 histomorphology, 37 type II cells, 281, 289, 297 acute monoblastic and monocytic leukemia, 535 pathogenesis, 39 unusual histologic variants, 282 acute monoblastic leukemia, 508, 513 allogeneic bone marrow transplant variants/subtypes, 280, 280 acute monocytic leukemia, 509 acute graft-versus-host disease, 44 anaplastic lymphoma kinase (ALK) acute myelogenous leukemia, 508 subcutaneous panniculitis-like T cell anaplastic large cell lymphoma, 280, 282, 283, case studies, 517, 517 lymphoma, 336 286 light microscopic findings, 509 allogeneic hematopoietic stem cell detection methods, 284 subtypes, 507, 534, 535 transplantation (allo-HSCT), cutaneous T lymphomatoid papulosis, 277, 281 acute myeloid leukemia, 509, 534 cell lymphoma, 20 rearrangement, 308 acute myelomonocytic leukemia, 535 alopecia, syringolymphoid hyperplasia with anaplastic lymphoma kine-positive diffuse large acute promyelocytic leukemia (APL), 534, 535 see syringolymphoid hyperplasia with B cell lymphoma, 283 adipocyte rimming alopecia anaplastic plasmacytoma see plasmablastic γ δ T cell lymphoma, 407, 410, 411 alopecia mucinosa, 98, 98–99 lymphoma subcutaneous panniculitis-like T cell case studies, 111–114, 111–114, 115, 117, 117 angiocentric cutaneous T cell lymphoma of lymphoma, 336, 343, 346 differential diagnosis, 98, 99 childhood, 416 adnexotropic mycosis fungoides, 240–241, 250, follicular mycosis fungoides, 240 angiocentric immunoproliferative lesions (AIL), 253 light microscopic findings, 99, 111, 113, 117 499 adnexotropic T cell dyscrasia, case study, 115, molecular studies, 99, 114, 116, 126 angiocentric T cell lymphoma, differential 115–116 phenotypic studies, 99, 112, 113, 114 diagnosis, 501 adult T cell leukemia/lymphoma, 473, 473–485 amyloidosis, nodular, 143 angioimmunoblastic lymphadenopathy with acute, 473, 473–475, 474, 479–480, 479–481 anaplastic large cell lymphoma, 280, 280–282, dysproteinemia see angioimmunoblastic T case studies, 477–483, 477–483 281 cell lymphoma chronic, 474, 474 activation antigens, 283 angioimmunoblastic T cell lymphoma, 486, clinical features, 473, 473–474 breast-implant-associated, 282 486–498, 489 differential diagnosis, 454, 474 case studies, 33, 33, 286–289, 286–289 architectural growth patterns, 487 follicular mucinosis, 475 categorization, 281 autoimmune diathesis, 486 HTLV-1-associated post-transplant, 419COPYRIGHTEDCD8-positive MATERIALcase studies, 491–496, 491–496 immune suppression, 474 case study, 297, 297 clinical features, 486, 486–487 lymphomatous, 473, 474, 482, 482, 483 phenotypic studies, 283, 284, 293, 294, 295, composite lymphoma, 487 pathogenesis, 475–476 297 differential diagnosis, 487 pathology, 474–475, 477, 479, 480 cytogenetics, 284, 302 diffuse large B cell lymphoma, 487 phenotypic studies, 475, 478 differential diagnosis, 316, 319, 437, 513 drug-induced, 486 prognosis, 474 intravascular, 219–220, 282–283 Epstein–Barr virus, 486–487, 488, 489 skin lesions, 474 light microscopic findings, 281–282, 286, 287, light microscopic findings, 487, 492, 495 smoldering, 474, 474, 477, 477, 478 288, 289 lymph node changes, 487, 491, 495 treatment, 475 lymphomatoid papulosis vs., 280 molecular studies, 488–489 236A/F7 see Fox P3 molecular studies, 301 pathogenesis, 489–490 aggressive natural killer cell lymphoma, 378, myxoid, 283, 305, 305, 306 phenotypic studies, 488, 491 380, 380, 391 pathogenesis, 284–285 primary cutaneous B cell lymphoma, 487 The Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin, Second Edition. Cynthia M. Magro, A. Neil Crowson and Martin C. Mihm. © 2016 John Wiley & Sons, Inc. Published 2016 by John Wiley & Sons, Inc. 541 bindex 541 19 November 2015 7:21 PM 279mm×216mm 542 Index angioimmunoblastic T cell (continued) bax, mycosis fungoides, 257 Berti’s lymphoma see primary cutaneous B cell(s) aggressive epidermotropic cytotoxic skin findings, 487, 491, 494 clonality assessment, 28 CD8+ T cell lymphoma therapy, 486 differentiation stage, 138 beta 1 integrin subunit see CD29 antigen vascular changes, 487, 494 lymphocytoma cutis, 66 bexarotene angioinvasion marginal zone lymphoma, 136, 145 adverse events, 17 γ δ T cell lymphoma, 409 paraffin-embedded tissue panels, 12 cutaneous T cell lymphoma, 15–16, 17 nasal natural killer cell/T cell lymphoma, 388 proliferation, 138 denileukin diftitox and, 17–18 type E lymphomatoid papulosis, 276, 278 V-D-J rearrangement, 23 mycosis fungoides, 15–16 angiolymphoid hyperplasia with eosinophilia B cell chronic lymphocytic leukemia (B-CLL), safety/efficacy, 16 (ALHE), 67–68 449–452, 450, 469 BF-1 antibody angiotropism, 169 case studies, 455–461, 455–461 definition, 9 γ δ T cell lymphoma, 407, 409 clinical features, 449–450 γ δ T cell lymphoma, 408, 411 annular lichenoid dermatosis of youth, 92 cytogenetics, 451, 467 Binet staging system, chronic lymphocytic antibodies, 13 molecular studies, 451 leukemia, 449 antibody drug conjugates (ADC), 19 morphology, 450, 455, 456, 457, 458, 459, 460, Birbeck granules, Langerhans sarcoma, 512 antihistamines 461 blastic marginal zone lymphoma, 140, 161, 162, marginal zone lymphoma, 134 pathogenesis, 452 188, 189, 194–195 reactive lymphoid hyperplasia induction, 134 phenotype, 451, 457, 459, 461 case study, 161, 161–163 antiphospholipid antibody syndrome, 45 prognosis, 450, 451 cytogenetic profile, 163, 194 anti-Ro-associated systemic lupus B cell hyperplasia de novo, 140, 194 erythematosus, 46 mycosis fungoides, 251 light microscopic findings, 140, 226, 229, 232 clinical features, 49 primary cutaneous CD4+ small/medium- phenotypic profile, 140 histopathology, 50 sized pleomorphic T cell lymphoma, 317 prognosis, 194 immunofluorescent findings, 50 B-cell lymphoid hyperplasia, 138 reactive germinal centers, 190 antithymocyte autoantibody, chronic B cell markers, definition, 10–11 subtypes, 140, 194 lymphocytic leukemia, 452 B cell neoplasms, classification, 138 blastic NK cell lymphoma see blastic antivirals, post-transplant lymphoproliferative bcl-1 plasmacytoid dendritic cell neoplasm disease, 418 blastoid mantle cell lymphoma, 230, 232 blastic NK-like T cell lymphoma see blastic API2 MALT1 fusion probe, 13 definition, 10 plasmacytoid dendritic cell neoplasm API2-MALT1 fusion protein, marginal zone mantle cell lymphoma, 226, 227, 233 blastic plasmacytoid dendritic cell neoplasm, lymphoma, 138 bcl-2 377, 379, 382–383, 383, 507, 510 apoptosis blastic marginal zone lymphoma, 162, 195 case study, 399, 399–400 acute graft-versus-host disease, 45 chronic lymphocytic leukemia, 451 light microscopic findings, 383 CD10 antigen, 196, 488 definition, 10 molecular studies, 383 mycosis fungoides, 257 diffuse large B cell lymphoma, leg type, 190, phenotypic studies, 383, 399, 400 systems, 257 202 blastoid mantle cell lymphoma, 226 apoptosis regulator B cell lymphoma 10 (BCL10) double-hit lymphoma, 197 case studies, 229, 229, 230, 232, 232 see Bcl-10 marginal zone lymphoma, 137, 150 cytogenetic studies, 233 APRIL, chronic lymphocytic leukemia, 451 precursor B cell lymphoblastic lymphoma, 212 BLIPM-1, diffuse large B cell lymphoma, leg arthropod-bite responses, 39 primary cutaneous follicle center lymphoma, type, 193 ataxia telangiectasia, 453 171, 172–173, 175, 183 BOB-1, lymphocyte-predominant Hodgkin ataxia telangiectasia mutated gene/protein bcl-2 IgH fusion probe, 13, 195 lymphoma, 437 (ATM) bcl-6 body-surface area (BSA) mantle cell lymphoma, 227, 228 definition, 10 calculation, 4, 245 T cell prolymphocytic leukemia, 454 diffuse large B cell lymphoma, 190 mycosis fungoides, 4, 236 atopic dermatitis, 41, 242, 244 diffuse large B cell lymphoma, leg type, 193 bone marrow erythrodermic, 244 follicular helper T cell lymphoma, 317 mycosis fungoides, 254 atypical fibroxanthoma, 515 Hodgkin lymphoma, 437, 442 myelodysplastic syndrome, 508 atypical lymphocytic lobular panniculitis, 100, marginal zone lymphoma, 137 bone marrow biopsy, 5 100–101, 101, 336, 337–338 primary cutaneous follicle center lymphoma, borderline CD30-positive lymphoproliferative case studies, 109, 109–110, 118, 118, 345, 173, 180, 183, 190, 191, 193, 204 disorders, 279, 290, 290, 291, 296 345–346 BCL7a, mycosis fungoides, 258 Borrelia burgdorferi differential diagnosis, 101, 337–338, 408 Bcl-10 marginal zone lymphoma, 138 light microscopic findings, 101,107–108, 109, 118 definition, 10 morphea, 55 molecular studies, 101, 127, 129 marginal zone lymphoma, 137 BRAF mutation, Langerhans cell histiocytosis, morphology,